Private Vista LLC acquired a new stake in shares of Danaher Co. (NYSE:DHR) in the second quarter, Holdings Channel.com reports. The firm acquired 1,560 shares of the conglomerate’s stock, valued at approximately $222,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. CX Institutional raised its position in Danaher by 188.7% in the first quarter. CX Institutional now owns 205 shares of the conglomerate’s stock worth $27,000 after purchasing an additional 134 shares in the last quarter. Lenox Wealth Management Inc. acquired a new position in Danaher in the first quarter worth about $40,000. Legacy Advisors LLC acquired a new position in Danaher in the first quarter worth about $55,000. Contravisory Investment Management Inc. acquired a new position in Danaher in the second quarter worth about $69,000. Finally, American Research & Management Co. acquired a new position in Danaher in the first quarter worth about $66,000. 78.84% of the stock is owned by institutional investors and hedge funds.
In other news, SVP William King sold 12,950 shares of the stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $129.92, for a total transaction of $1,682,464.00. Following the sale, the senior vice president now directly owns 29,070 shares of the company’s stock, valued at $3,776,774.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Mitchell P. Rales purchased 1,900 shares of the firm’s stock in a transaction dated Friday, May 10th. The shares were bought at an average cost of $130.78 per share, for a total transaction of $248,482.00. The disclosure for this purchase can be found here. Insiders have sold 392,121 shares of company stock worth $53,603,339 over the last three months. 11.40% of the stock is owned by insiders.
Danaher (NYSE:DHR) last issued its quarterly earnings data on Thursday, July 18th. The conglomerate reported $1.19 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.15 by $0.04. The firm had revenue of $5.16 billion for the quarter, compared to analysts’ expectations of $5.09 billion. Danaher had a net margin of 12.22% and a return on equity of 11.53%. The company’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.15 earnings per share. As a group, sell-side analysts expect that Danaher Co. will post 4.79 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, July 26th. Stockholders of record on Friday, June 28th were paid a dividend of $0.17 per share. The ex-dividend date was Thursday, June 27th. This represents a $0.68 annualized dividend and a dividend yield of 0.49%. Danaher’s dividend payout ratio (DPR) is currently 15.04%.
DHR has been the subject of several recent research reports. Robert W. Baird increased their price target on shares of Danaher from $131.00 to $148.00 and gave the stock an “outperform” rating in a research report on Friday, July 19th. Piper Jaffray Companies upped their price objective on shares of Danaher from $148.00 to $153.00 and gave the stock a “neutral” rating in a research note on Thursday, July 18th. Needham & Company LLC reaffirmed a “buy” rating and set a $155.00 price objective (up from $142.00) on shares of Danaher in a research note on Friday, July 19th. Wolfe Research initiated coverage on shares of Danaher in a research note on Thursday, May 30th. They set an “outperform” rating on the stock. Finally, Argus upped their price objective on shares of Danaher to $165.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $143.54.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Featured Article: Consumer behavior in bull markets
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.